Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1806 results
December 2017
-
Story Access to Healthcare
Pioneering business approach expands healthcare in Indian villages
Healthy Family program combines health education with improved access to doctors and medicines.
-
Story Patient Perspectives
One boy’s quest to battle cancer
After a diagnosis of childhood cancer, Ryan faced the diagnosis and treatment of leukemia head- on with the support of his family and community.
-
Press release
Sandoz announces new Phase I data showing proposed biosimilar pegfilgrastim matches reference medicine
Phase I study demonstrates matching pharmacokinetic (PK), pharmacodynamic (PD), safety and immunogenicity profiles of Sandoz biosimilar pegfilgrastim and reference medicine Pegfilgrastim is a… -
Press release
Novartis tender offer for Advanced Accelerator Applications commences
Basel, December 7, 2017 -Novartis AG (NYSE: NVS) ("Novartis") today announced that its direct and indirect subsidiary, Novartis Groupe France S.A., a société anonyme organized under the laws of… -
Press release
Kisqali® first and only CDK4/6 inhibitor to show superior efficacy vs. oral endocrine therapy as 1L treatment in randomized Phase III trial in premenopausal women with HR+/HER2- advanced breast cancer
Kisqali plus an oral endocrine partner demonstrated significant efficacy with sustained benefit of nearly two years (median PFS 23.8 vs 13.0 months for endocrine therapy alone) and… -
Story Discovery
Researchers overcome hurdles to test experimental malaria drug
The race is on to find a new treatment before resistance to today’s drugs becomes widespread.
November 2017
-
Featured News
Exploring the future of access to healthcare in lower-income countries
The third Novartis Social Business stakeholder dialogue took place on November 21 in Basel. -
Press release
Novartis' Cosentyx® is first biologic to show long-term efficacy in nail and palmoplantar psoriasis, which can impact up to 90% of psoriasis patients
Unique Cosentyx® (secukinumab) data reinforce treatment option for up to 90% of psoriasis patients who may develop nail or palmoplantar psoriasis[1]-[4] Cosentyx results represent the first data… -
Press release
Novartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab (AMG334) in migraine prevention
Patients with episodic migraine taking erenumab reported significant and meaningful benefits over six months, with reduced migraine days and acute medication use Fifty percent of patients… -
Featured News
Biosimilar drugs have the potential to save more than USD 54 billion
RAND Corporation and the Moran Company issued reports discussing the cost savings associated with biosimilars.
-
Press release
Novartis' Ultibro® Breezhaler® significantly improved COPD patients' lung function after direct switch from Seretide®
New data showed switching moderate-to-severe, symptomatic COPD patients from Seretide®* to Ultibro® Breezhaler® improved lung function and was well tolerated. The FLASH… -
Press release
Novartis drug Tasigna® (nilotinib) secures EU approval for first and second-line treatment of Ph+ CML-CP in children
Tasigna is the first and only second-generation tyrosine kinase inhibitor approved in the EU for the treatment of Ph+ CML-CP in children Approval builds on a series of Tasigna regulatory…